Clinical trial
A Phase 1b/2 Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP-104GI in Adults With Eosinophilic Esophagitis (RESOLVE)
NCT05608681 is registered in ClinicalTrials.gov with Eupraxia Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2 Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP-104GI in Adults With Eosinophilic Esophagitis (RESOLVE)
- Lead sponsor
- Eupraxia Pharmaceuticals Inc.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- March 31, 2023
- Completion date
- December 31, 2026
- Enrollment
- 117 (estimated)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.